702
Participants
Start Date
November 12, 2020
Primary Completion Date
June 1, 2027
Study Completion Date
June 1, 2027
AZD5305
Oral PARP inhibitor
Paclitaxel
IV Anti-microtubule agent
Carboplatin
IV Platinum chemotherapeutic
T- Dxd
IV Antibody-drug conjugate
Dato-DXd
IV Antibody-drug conjugate
Camizestrant
Oral SERD Molecule
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Melbourne
Research Site, Heidelberg
Research Site, New York
Research Site, Prague
Research Site, Milan
Research Site, Milan
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Pozuelo de Alarcón
Research Site, Málaga
Research Site, Padua
Research Site, Seville
Research Site, Modena
Research Site, Chernivtsі
Research Site, Oklahoma City
Research Site, Ivano-Frankivsk
Research Site, Houston
Research Site, Napoli
Research Site, Uzhhorod
Research Site, Beijing
Research Site, Moscow
Research Site, Moscow
Research Site, Moscow
Research Site, Changchun
Research Site, Moscow
Research Site, Harbin
Research Site, Shanghai
Research Site, Shanghai
Research Site, Jining
Research Site, Chongqing
Research Site, Changsha
Research Site, Wuhan
Research Site, Guangzhou
Research Site, Chengdu
Research Site, Xi'an
Research Site, Boston
Research Site, Boston
Research Site, Vancouver
Research Site, Toronto
Research Site, Montreal
Research Site, Montreal
Research Site, Shandong
Research Site, Taiyuan
Research Site, Brno
Research Site, Roma
Research Site, Chūōku
Research Site, Kōtoku
Research Site, Bydgoszcz
Research Site, Gdansk
Research Site, Gdynia
Research Site, Grzepnica
Research Site, Lodz
Research Site, Torun
Research Site, Warsaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Kyiv
Research Site, Cambridge
Research Site, Manchester
Research Site, Oxford
Research Site, Sutton
Lead Sponsor
AstraZeneca
INDUSTRY